Molecular determinants of hERG potassium channel inhibition by disopyramide

Journal of Molecular and Cellular Cardiology

Volumn 52, Issue 1, 2012, Pages 185-195

  El Harchi, Aziza ^a   Zhang, Yi H ^a   Hussein, Leyla ^a   Dempsey, Christopher E ^a   Hancox, Jules C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Antiarrhythmic; Disopyramide; Docking; HERG; I Kr; Long QT; QT interval; Rapid delayed rectifier; Short QT

Indexed keywords

ALANINE; DISOPYRAMIDE; POTASSIUM CHANNEL HERG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE MUTATION; HUMAN; IC 50; LONG QT SYNDROME; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION;

ACTION POTENTIALS; AMINO ACID SEQUENCE; ANTI-ARRHYTHMIA AGENTS; DISOPYRAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; HEK293 CELLS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN CONFORMATION;

EID: 84155189025     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.09.021     Document Type: Article

References (68)

1. Tamargo J., Caballero R., Gomez R., Valenzuela C., Delpon E. Pharmacology of cardiac potassium channels. Cardiovasc Res 2004, 62(1):9-33.
2. + current. J Gen Physiol 1990, 96:195-215.
3. Kr potassium channel. Cell 1995, 81:299.
4. Trudeau M.C., Warmke J.W., Ganetzky B., Robertson G.A. HERG, an inward rectifier in the voltage-gated potassium channel family. Science 1995, 269:92-95.
5. Modell S.M., Lehmann M.H. The long QT syndrome family of cardiac ion channelopathies: a HuGE review. Genet Med Mar 2006, 8(3):143-155.
6. Schimpf R., Wolpert C., Gaita F., Giustetto C., Borggrefe M. Short QT syndrome. Cardiovasc Res Aug 15 2005, 67(3):357-366.
7. Finlayson K., Witchel H.J., McCulloch J., Sharkey A. Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur J Pharmacol 2004, 500:129-142.
8. Sanguinetti M.C., Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature Mar 23 2006, 440(7083):463-469.
9. Witchel H.J., Hancox J.C. Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium channel. Clin Exp Pharmacol Physiol 2000, 27:753-766.
10. Sanguinetti M.C., Mitcheson J.S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. TIPS 2005, 26(3):119-124.
11. Mitcheson J.S., Chen J., Sanguinetti M.C. Trapping of a methanesufonanlide by closure of the HERG potassium channel activation gate. J Gen Physiol 2000, 115:229-240.
12. Mitcheson J.S., Chen J., Lin M., Culberson C., Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 2000, 97:12329-12333.
13. Virag L., Varro A., Papp J.G. Effect of disopyramide on potassium currents in rabbit ventricular myocytes. Naunyn-Schmiedeberg's Arch Pharmacol 1998, 357:268-275.
14. Paul A.A., Witchel H.J., Hancox J.C. Inhibition of HERG potassium channel current by the Class 1a antiarrhythmic agent disopyramide. Biochem Biophys Res Commun 2001, 280:1243-1250.
15. + channels involved in variant 1 short QT syndrome. J Mol Cell Cardiol 2006, 41:563-566.
16. + channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol 2008, 155:957-966.
17. Lazarra R. Antiarrhythmic drugs and torsade de pointes. Eur Heart J 1993, 14:88-92.
18. Furushima H., Niwano S., Chinushi M., Ohhira K., Abe A., Aizawa Y. Relation between bradycardia dependent long QT syndrome and QT prolongation by disopyramide in humans. Heart 1998, 79:56-58.
19. Yap Y.G., Camm A.J. Drug induced QT prolongation and torsades de pointes. Heart 2003, 89:1363-1372.
20. + channel inhibition by disopyramide in patients with a short QT-1 syndrome: a pilot study. J Cardiovasc Electrophysiol 2007, 18:1157-1160.
21. Brugada R., Hong K., Dumaine R., Cordeiro J., Gaita F., Borggrefe M., et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004, 109:30-35.
22. Hancox J.C., McPate M.J., El Harchi A., Zhang Y.H. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 2008, 119:118-132.
23. Lees-Miller J.P., Duan Y., Teng G.Q., Duff H.J. Molecular determinant of high affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol 2000, 57:367-374.
24. Perrin M.J., Kuchel P.W., Campbell T.J., Vandenberg J.I. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels. Mol Pharmacol 2008, 74:1443-1452.
25. Milnes J.T., Crociani O., Arcangeli A., Hancox J.C., Witchel H.J. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 2003, 139(5):887-898.
26. + channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. Biochem Biophys Res Commun 2004, 325:883-891.
27. + channel. J Mol Cell Cardiol 2004, 36(5):701-705.
28. + channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37°C. Biochem Biophys Res Commun 2005, 334:441-449.
29. Zhou Z., Gong Q., Ye B., Fan Z., Makielski J.C., Robertson G.A., et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 1998, 74:230-241.
30. El Harchi A., McPate M.J., Zhang Y.H., Zhang H., Hancox J.C. Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndrome. J Mol Cell Cardiol 2009, 137:83-85.
31. Jiang Y., Lee A., Chen J., Cadene M., Chait B.T., MacKinnon R. Crystal structure and mechanism of a calcium-gated potassium channel. Nature May 30 2002, 417(6888):515-522.
32. Witchel H.J., Dempsey C.E., Sessions R.B., Perry M.D., Milnes J.T., Hancox J.C., et al. The low-potency, voltage-dependent HERG channel blocker propafenone - molecular determinants and drug trapping. Mol Pharmacol 2004, 66:1201-1212.
33. + channel: accessibility to F656 and Y652. Biochem Biophys Res Commun 2006, 341:500-506.
34. Kr. Implications for torsade de pointes and reverse use-dependence. Circulation 1996, 93(3):407-411.
35. +]o and C-type inactivation. FEBS Lett 1997, 417:43-47.
36. Barrows B., Cheung K., Bialobrzeski T., Foster J., Schulze J., Miller A. Extracellular potassium dependency of block of HERG by quinidine and cisapride is primarily determined by the permeant ion and not by inactivation. Channels (Austin) Jul 2009, 3(4):239-248.
37. Sanchez-Chapula J.A., Ferrer T., Navarro-Polanco R.A., Sanguinetti M.C. Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol Pharmacol May 2003, 63(5):1051-1058.
38. Kamiya K., Niwa R., Mitcheson J.S., Sanguinetti M.C. Molecular determinants of HERG channel block. Mol Pharmacol 2006, 69:1709-1716.
39. Perry M., Stansfeld P.J., Leaney J., Wood C., de Groot M.J., Leishman D., et al. Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs. Mol Pharmacol Feb 2006, 69(2):509-519.
40. + channel blockade by the fluoroquinolone antibiotic moxifloxacin. Br J Pharmacol Apr 2006, 147(8):905-916.
41. Ferrer-Villada T., Navarro-Polanco R.A., Rodriguez-Menchaca A.A., avides-Haro D.E., Sanchez-Chapula J.A. Inhibition of cardiac HERG potassium channels by antidepressant maprotiline. Eur J Pharmacol Feb 15 2006, 53(1-3):1-8.
42. Mitcheson J.S., Perry S. Molecular determinants of high affinity drug binding to HERG channels. Curr Opin Drug Discov Devel 2003, 6:667-674.
43. Arechiga I.A., Barrio-Echavarria G.F., Rodriguez-Menchaca A.A., Moreno-Galindo E.G., Decher N., Tristani-Firouzi M., et al. Kv1.5 open channel block by the antiarrhythmic drug disopyramide: molecular determinants of block. J Pharmacol Sci 2008, 108:49-55.
44. Mason P.E., Dempsey C.E., Vrbka L., Heyda J., Brady J.W., Jungwirth P. Specificity of ion-protein interactions: complementary and competitive effects of tetrapropylammonium, guanidinium, sulfate, and chloride ions. J Phys Chem B Mar 12 2009, 113(10):3227-3234.
45. Dempsey C.E., Mason P.E., Jungwirth P. Complex ion effects on polypeptide conformational stability: chloride and sulfate salts of guanidinium and tetrapropylammonium. J Am Chem Soc May 18 2011, 133(19):7300-7303.
46. Stansfeld P.J., Gedeck P., Gosling M., Cox B., Mitcheson J.S. Drug block of the hERG potassium channel: insight from modeling. Proteins 2007, 68:568-580.
47. + channel by antimalarial drug, primaquine. Arch Pharm Res May 2010, 33(5):769-773.
48. + channels by vesnarinone. Mol Pharmacol 2001, 60:244-253.
49. Siebrands C.C., Friederich P. Structural requirements of human ether-a-go-go-related gene channels for block by bupivacaine. Anesthesiology Mar 2007, 106(3):523-531.
50. Rodriguez-Menchaca A., Ferrer-Villada T., Lara J., Fernandez D., Navarro-Polanco R.A., Sanchez-Chapula J.A. Block of HERG channels by berberine: mechanisms of voltage- and state-dependence probed with site-directed mutant channels. J Cardiovasc Pharmacol Jan 2006, 47(1):21-29.
51. + channel. Mol Cell Biochem Jan 2009, 320(1-2):125-131.
52. Wolpert C., Schimpf R., Giustetto C., Antzelevitch C., Cordeiro J.M., Dumaine R., et al. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol 2005, 16:54-58.
53. Mergenthaler J., Haverkamp W., Huttenhofer A., Skryabin B.V., Mubhoff U., Borggrefe M., et al. Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel. Naunyn-Schmiedeberg's Arch Pharmacol 2001, 363:472-480.
54. Paul A.A., Witchel H.J., Hancox J.C. Inhibition of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J Pharmacol 2002, 136:717-729.
55. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003, 58:32-45.
56. Zema M.J. Serum drug concentration and adverse effects in cardiac patients after administration of a new controlled-release disopyramide preparation. Ther Drug Monit 1984, 6:192-198.
57. Staudacher I., Schweizer P.A., Katus H.A., Thomas D. hERG: protein trafficking and potential for therapy and drug side effects. Curr Opin Drug Discov Devel Jan 2010, 13(1):23-30.
58. Wible B.A., Hawryluk P., Ficker E., Kuryshev Y.A., Kirsch G., Brown A.M. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods Jul 2005, 52(1):136-145.
59. + current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine. Naunyn Schmiedebergs Arch Pharmacol May 2010, 381(5):385-400.
60. + channel-associated cardiac effects of the antidepressant drug desipramine. Naunyn Schmiedebergs Arch Pharmacol Feb 2011, 383(2):119-139.
61. Dumaine R., Antzelevitch C. Disopyramide: although potentially life-threatening in the setting of long QT, could it be life-saving in short QT syndrome?. J Mol Cell Cardiol 2006, 41:422-423.
62. Gaita F., Giustetto C., Bianchi F., Schimpf R., Haissaguerre M., Calo L., et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol 2004, 43:1494-1499.
63. Ficker E., Jarolimek W., Kiehn J., Baumann A., Brown A.M. Molecular determinants of dofetilide block of HERG K channels. Circ Res 1998, 82:386-395.
64. + channels. Mol Pharmacol Dec 2001, 60(6):1343-1348.
65. Kr inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome. Cardiovasc Res 2005, 67:498-509.
66. Zou A., Xu Q.P., Sanguinetti M.C. A mutation in the pore region of HERG K channels expressed in Xenopus oocytes reduces rectification by shifting the voltage dependence of inactivation. J Physiol 1998, 509(1):129-137.
67. Chen J., Seebohm G., Sanguinetti M.C. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and EAG potassium channels. Proc Natl Acad Sci U S A 2002, 99:12329-12333.
68. + is required for the inactivation-induced high-affinity binding of cisapride to HERG channels. Mol Pharmacol Sep 2005, 68(3):855-865.